Oncopeptides has submitted an application to the European Medicines Agency, EMA, for conditional marketing authorization of melflufen (melphalan flufenamide) in the EU, based on the phase 2 HORIZON study in relapsed refractory multiple myeloma. Pending a positive validation from the EMA, melflufeAlready a subscriber Login You have read all your…